Stevens Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Stevens Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-16,329	Closed	-$60K	–	1261
2016 Q1	$60K	Buy	+16,329	New	+$101K	﹤0.01%	845
2014 Q3	–	Sell	-14,439	Closed	-$463K	–	1389
2014 Q2	$463K	Buy	14,439 +8,050	+126%	+$300K	0.01%	695
2014 Q1	$295K	Buy	+6,389	New	+$375K	0.01%	796

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens Capital Management's AEGR Position: Q2 2016 in Review

Stevens Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 16,329 shares — an estimated $60K sold.

Stevens Capital Management first reported a position in AEGR in Q1 2014 and held it in 3 quarters. The position peaked at $463K in Q2 2014. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Stevens Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Stevens Capital Management sold 16,329 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $60K.
Stevens Capital Management first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 3 quarters.
Stevens Capital Management's Aegerion Pharmaceuticals position peaked at $463K in Q2 2014.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Stevens Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.